Smart Phone Reader Detects Common Pathogens
|
By LabMedica International staff writers Posted on 10 May 2018 |

Image: The low-cost, portable laboratory on a phone that can interpret results from a microplate assay (Photo courtesy of Washington State University).
In rural or low resource areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.
A low-cost, portable laboratory on a phone has been developed that works nearly as well as clinical laboratories to detect common viral and bacterial infections. The work could lead to faster and lower-cost laboratory results for fast-moving viral and bacterial epidemics.
Bioengineers at Washington State University (Pullman, WA, USA) and their colleagues developed an ultra-low-cost clinically accurate mobile phone microplate reader (mReader), and clinically validated this optical device for 12 infectious disease tests. The mReader optically reads 96 samples on a microplate at one time. The team tested 771 de-identified patient samples for 12 serology assays for bacterial/viral infections. The mReader and the clinical instrument blindly read and analyzed all tests in parallel.
The scientists evaluated the analytical accuracy and the diagnostic performance of the mReader across the clinical reportable categories by comparison with clinical laboratorial testing results. The mReader exhibited 97.6% to 99.9% analytical accuracy and <5% coefficient of variation (CV). The positive percent agreement (PPA) in all 12 tests achieved 100%, negative percent agreement (NPA) was higher than 83% except for one test (42.9%), and overall percent agreement (OPA) ranged 89.3% to100%. The team was able to build the device for about USD 50, but the manufacturing cost would probably be lower than that.
The authors envision the mReader can benefit underserved areas/populations and low-resource settings in rural clinics/hospitals at a low cost with clinical-level analytical quality. It has the potential to improve health access, speed up healthcare delivery, and reduce health disparities and education disparities by providing access to a low-cost spectrophotometer. The study was published on March 23, 2018, in the journal Clinica Chimica Acta.
Related Links:
Washington State University
A low-cost, portable laboratory on a phone has been developed that works nearly as well as clinical laboratories to detect common viral and bacterial infections. The work could lead to faster and lower-cost laboratory results for fast-moving viral and bacterial epidemics.
Bioengineers at Washington State University (Pullman, WA, USA) and their colleagues developed an ultra-low-cost clinically accurate mobile phone microplate reader (mReader), and clinically validated this optical device for 12 infectious disease tests. The mReader optically reads 96 samples on a microplate at one time. The team tested 771 de-identified patient samples for 12 serology assays for bacterial/viral infections. The mReader and the clinical instrument blindly read and analyzed all tests in parallel.
The scientists evaluated the analytical accuracy and the diagnostic performance of the mReader across the clinical reportable categories by comparison with clinical laboratorial testing results. The mReader exhibited 97.6% to 99.9% analytical accuracy and <5% coefficient of variation (CV). The positive percent agreement (PPA) in all 12 tests achieved 100%, negative percent agreement (NPA) was higher than 83% except for one test (42.9%), and overall percent agreement (OPA) ranged 89.3% to100%. The team was able to build the device for about USD 50, but the manufacturing cost would probably be lower than that.
The authors envision the mReader can benefit underserved areas/populations and low-resource settings in rural clinics/hospitals at a low cost with clinical-level analytical quality. It has the potential to improve health access, speed up healthcare delivery, and reduce health disparities and education disparities by providing access to a low-cost spectrophotometer. The study was published on March 23, 2018, in the journal Clinica Chimica Acta.
Related Links:
Washington State University
Latest Microbiology News
- Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
- Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
- Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
- Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
- Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
- Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
- Genomic Workflow Identifies Fungal Pathogens Before Blood Cultures Turn Positive
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
Channels
Clinical Chemistry
view channel
Study Links Saliva-Based Epigenetic Signals to OCD Treatment Outcomes
Obsessive-compulsive disorder (OCD) causes unwanted, recurring thoughts and repetitive behaviors that can severely disrupt daily life. Exposure-based psychotherapy is among the most effective treatments,... Read more
New One-Step Syphilis Test Could Enable Earlier Detection and Faster Treatment
Syphilis can be difficult to diagnose because its symptoms may resemble other diseases and appear and disappear without treatment. Undetected infection can continue causing harm, spread to partners and... Read moreMolecular Diagnostics
view channel
Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis
Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more
Clinical Trial Evaluates Liquid Biopsy for Early-Stage Breast Cancer Detection
Breast cancer screening relies primarily on mammography, but abnormal findings can lead to additional imaging, biopsy, or repeat imaging after six months, creating anxiety and potentially delaying treatment... Read more
RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more
Modeling Study Shows Blood-Based CRC Screening Could Prevent More Deaths Than Stool Tests
Colorectal cancer (CRC) screening depends on patient participation and completion of follow-up colonoscopy after an abnormal noninvasive result. Access barriers can make both steps difficult, particularly... Read moreHematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read moreImmunology
view channel
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read morePathology
view channel
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read more
Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
Digital pathology is reshaping how laboratories manage case review, image analysis, and collaboration. As diagnostic workflows become more complex, pathology teams need platforms that can support digital... Read moreIndustry
view channel
Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more







